Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach

被引:45
作者
Régulier, E [1 ]
Paul, S [1 ]
Marigliano, M [1 ]
Kintz, J [1 ]
Poitevin, Y [1 ]
Ledoux, C [1 ]
Roecklin, D [1 ]
Cauet, G [1 ]
Calenda, V [1 ]
Homann, HE [1 ]
机构
[1] Transgene SA, F-67082 Strasbourg, France
关键词
angiogenesis; therapy; tumor; recombinant adenovirus;
D O I
10.1038/sj.cgt.7700278
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Based on the observation that the growth of solid tumors is dependent on the formation of new blood vessels, therapeutic strategies aimed at inhibiting angiogenesis have been proposed. A number of proteins with angiostatic activity have been described, but their development as therapeutic agents has been hampered by difficulties in their production and their poor pharmacokinetics. These limitations may be resolved using a gene therapy approach whereby the genes are delivered and expressed in vivo. Here we compared adenoviral delivery of endostatin, proliferin-related protein (PRP), and interferon-inducible protein 10 (IP10) genes. Recombinant adenoviruses carrying the three angiostatic genes express biologically active gene products as determined in vitro in endothelial cell proliferation and migration assays, and in vivo by inhibition of neoangiogenesis in rat chambers. Eradication of established tumors in vivo, in the murine B16F10 melanoma model in immunocompetent mice, was not achieved by intratumoral injection of the different vectors. However, the combination of intravenous plus intratumoral injections allowed rejection of tumors. Ad-PRP or Ad-IP10 were significantly more efficient than Ad-endostatin, leading to complete tumor rejection and prolonged survival in a high proportion of treated animals. These data support the use of in vivo gene delivery approaches to produce high-circulating and local levels of antiangiogenic agents for the therapy of local and metastatic human tumors.
引用
收藏
页码:45 / 54
页数:10
相关论文
共 56 条
[11]   Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli [J].
Chartier, C ;
Degryse, E ;
Gantzer, M ;
Dieterle, A ;
Pavirani, A ;
Mehtali, M .
JOURNAL OF VIROLOGY, 1996, 70 (07) :4805-4810
[12]  
Chen QR, 1999, CANCER RES, V59, P3308
[13]   CHARACTERIZATION OF PROLIFERIN-RELATED PROTEIN [J].
COLOSI, P ;
SWIERGIEL, JJ ;
WILDER, EL ;
OVIEDO, A ;
LINZER, DIH .
MOLECULAR ENDOCRINOLOGY, 1988, 2 (06) :579-586
[14]  
Dhanabal M, 1999, CANCER RES, V59, P189
[15]  
Duda DG, 2000, CANCER RES, V60, P1111
[16]  
Erbs P, 2000, CANCER RES, V60, P3813
[17]  
Feldman AL, 2000, CANCER RES, V60, P1503
[18]   Clinical applications of angiogenic growth factors and their inhibitors [J].
Ferrara, N ;
Alitalo, K .
NATURE MEDICINE, 1999, 5 (12) :1359-1364
[19]   Seminars in medicine of the Beth Israel Hospital, Boston - Clinical applications of research on angiogenesis [J].
Folkman, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (26) :1757-1763
[20]   ANTI-ANGIOGENESIS - NEW CONCEPT FOR THERAPY OF SOLID TUMORS [J].
FOLKMAN, J .
ANNALS OF SURGERY, 1972, 175 (03) :409-&